经典霍奇金淋巴瘤:影响新兴疗法的病理生物学特征
Mohamed Nazem Alibrahim1, Annunziata Gloghini2, Antonino Carbone3
1Faculty of Medicine, Zagazig University, Egypt.
Blood reviews
|February 4, 2025
概括
经典霍奇金淋巴瘤 (cHL) 涉及独特的霍奇金里德-斯特恩伯格 (HRS) 细胞,这些细胞创造了一个免疫抑制瘤微环境. 新型疗法提供了希望,但cHL异质性需要进一步研究,以改善治疗策略和降低毒性.
科学领域:
- 血液学和瘤学研究
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 经典霍奇金淋巴瘤 (cHL) 具有CD30+/CD15+霍奇金里德-斯特恩伯格 (HRS) 细胞的特征,这些细胞构成瘤的一小部分,但严重影响免疫抑制瘤微环境 (TME).
- 虽然辐射和化疗等传统疗法可以实现cHL的高治愈率,但与治疗相关的显著毒性仍然存在,需要在疗效和安全之间取得平衡.
- 最近对HRS细胞的分子洞察力刺激了向治疗的发展,包括检查点抑制剂和抗体药物合物,在复发或耐药病例中表现出显著的疗效.
研究的目的:
- 审查经典霍奇金淋巴瘤中HRS细胞的起源,形态,表型和遗传特征.
- 探索HRS细胞的病理生物学特征,包括生物标志物和爱斯坦-巴尔病毒 (EBV) 的作用.
- 评估目前和新兴的cHL治疗策略,考虑到由HRS细胞生物学和TME驱动的异质性.
主要方法:
- 对古典霍奇金淋巴瘤现有文献的综述,重点关注霍奇金里德-斯特恩伯格细胞生物学.
- 分析病理生物学特征,生物标志物和爱斯坦-巴尔病毒的影响.
- 评估标准和新型治疗方法,包括从单细胞RNA测序和循环瘤DNA分析等先进技术的见解.
主要成果:
- 尽管HRS细胞的频率较低,但它们对cHL病原和免疫抑制TME的产生至关重要.
- 了解HRS细胞生物学方面的进步导致了有效的新疗法,特别是在难以治疗的cHL.
- 由于HRS细胞生物学和TME复杂性,cHL的异质性仍然是治疗优化的一个挑战.
结论:
- 了解HRS细胞及其微环境的复杂生物学对于开发更有效,更少毒性的cHL治疗至关重要.
- 新兴技术为解决cHL异质性和个性化治疗策略提供了有前途的途径.
- 对新型方法的持续研究对于提高治愈率至关重要,同时尽量减少cHL患者的长期不良影响.
相关概念视频
01:27Cytotoxic T Cells-mediated Immune Response
833
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
833
01:27Tumor Immunotherapy
464
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
464
02:49Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K